VIII. 14. Beta-Blockers (Beta-Adrenoceptor Antagonists)

Beta-blockers slow gut transit and interrupt the stress-hormone signal that gut bacteria also respond to — and may even tone down the aggressiveness of pathogens.

Beta-Blockers – The Drug Born of Grief, and What It Does Beneath the Heart

Beta-blockers transformed the management of cardiovascular disease — and turn out to interact with the gut microbiota through a biological axis that their inventor could not have imagined. [245]

James Whyte Black was not driven primarily by curiosity. He was driven by grief. Black, a Scottish pharmacologist working for ICI Pharmaceuticals in the late 1950s, had watched his father die of a heart attack — and the experience crystallised a clinical hypothesis: if the heart’s ruinous response to emotional and physical stress was mediated by adrenaline acting on beta-adrenergic receptors, then a drug that blocked those receptors might prevent the spiral of ischaemia and arrhythmia that kills. By 1964, Black had synthesised propranolol — the first clinically successful beta-blocker. It transformed the treatment of angina, hypertension, and arrhythmia. Black received the Nobel Prize in Physiology or Medicine in 1988. What neither Black nor his Nobel committee could have known was that the adrenergic signalling system he had set out to interrupt in the myocardium operates in parallel in the intestinal wall — and that the bacteria living in the gut below the heart also possess adrenergic receptor-like proteins that respond to catecholamines.

Beta-adrenoceptors are distributed throughout the gastrointestinal tract. Beta-2 receptors modulate intestinal smooth muscle relaxation, peristaltic frequency, and mucosal secretion. Non-selective beta-blockade (propranolol, carvedilol) slows intestinal transit — an effect that is clinically well recognised but rarely discussed in the context of microbiota. Transit time is one of the most powerful ecological determinants of gut microbial community composition: slower transit increases colonic fermentation time, shifts pH, alters substrate availability, and changes the selective pressure on resident taxa.

The relationship between catecholamines and gut bacteria is not merely indirect. Gut bacteria — including Escherichia coli, Campylobacter jejuni, Enterococcus faecalis, and Pseudomonas aeruginosa — possess adrenergic receptor-like proteins that bind host catecholamines and respond by upregulating virulence gene expression, biofilm formation, and growth rate. This phenomenon, termed interkingdom signalling, represents a direct mechanism by which host stress physiology modifies bacterial behaviour. Beta-blockers, by blocking adrenergic signalling at the gut wall, reduce catecholamine-mediated bacterial virulence activation. Propranolol has shown dose-dependent inhibition of Pseudomonas aeruginosa quorum-sensing-dependent biofilm formation in preclinical models, [246] and non-selective beta-blockade in cirrhotic patients is associated with reduced bacterial translocation across the gut wall.

In patients with heart failure — the largest indication group for chronic beta-blocker therapy — gut dysbiosis is an established feature of the disease. Reduced cardiac output causes splanchnic hypoperfusion, mucosal ischaemia, and increased intestinal permeability, driving a cycle of bacterial translocation and systemic inflammation that worsens cardiac function. Beta-blockers, by improving cardiac output over time, may partially reverse this ischaemia-driven gut barrier failure. Carvedilol has been associated with reduced circulating endotoxin and improved gut barrier integrity in heart failure patients beyond its haemodynamic effects, [247] suggesting a direct gut-barrier-protective action through combined beta- and alpha-1 blockade.

For post-FMT patients on beta-blockers, the primary consideration is motility. Slowed colonic transit prolongs the residence time of donor-derived organisms, which may in theory support engraftment by extending ecological contact time with the mucosa. However, the same motility slowing increases the risk of small intestinal bacterial overgrowth (SIBO) — particularly when combined with concurrent proton pump inhibitor use. The combination of beta-blocker and PPI in a post-FMT patient represents the highest-risk motility–acid combination and should be reviewed at each clinical checkpoint.

Supporting Gut Health During Beta-Blocker Therapy

In clinical microbiota care, beta-blocker use is flagged primarily as a motility-modifying factor. The clinical tasks are: identifying the beta-blocker type (selective vs non-selective), documenting any concurrent PPI use, and monitoring for symptoms of slowed transit — bloating, distension, and altered bowel frequency.

Non-selective beta-blockers (propranolol, carvedilol) have broader gut wall effects than selective beta-1 agents (metoprolol, bisoprolol). In patients with pre-existing motility vulnerability, a clinical discussion about the choice of beta-blocker type — where cardiovascular equivalence allows — may be appropriate.

Dietary fibre intake ≥25g/day is particularly important in beta-blocker users to maintain colonic transit and fermentation dynamics despite motility slowing. Physical activity within cardiovascular tolerance counteracts beta-blocker-mediated intestinal slowing and supports microbial diversity.

If a patient on beta-blockers is also taking a PPI during FMT consolidation, the clinical team should review the necessity of PPI continuation at each monitoring visit — the combined effect represents a compounding risk for SIBO and engraftment disruption.

Transition between beta-blocker agents should be communicated to the FMT clinical team, as microbiota effects differ between agents and may alter the microbiota trajectory during consolidation.

Microbiota Effects

• Beta-2 adrenoceptor blockade slows gastrointestinal transit, increasing colonic fermentation time and altering substrate availability — an ecologically significant indirect modifier of gut microbial community composition. [245]
• Gut bacteria including Escherichia coli, Pseudomonas aeruginosa, and Enterococcus species possess adrenergic receptor-like proteins that respond to catecholamines; non-selective beta-blockers interfere with this interkingdom signalling, reducing catecholamine-driven virulence gene expression and biofilm formation. [246]
• In heart failure patients, beta-blocker therapy may partially reverse gut dysbiosis driven by splanchnic hypoperfusion and mucosal ischaemia, through improvement of cardiac output and restoration of gut perfusion. [247]
• Carvedilol is associated with reduced serum endotoxin and improved gut barrier integrity in heart failure patients, consistent with a direct gut-barrier-protective effect beyond haemodynamic action. [247]
• Propranolol inhibits quorum-sensing-dependent biofilm formation in Pseudomonas aeruginosa in vitro, identifying a potential direct anti-pathobiont mechanism. [246]
• Slowed gut transit in chronic beta-blocker users, particularly with concurrent proton pump inhibitor use, increases the risk of small intestinal bacterial overgrowth — a clinically significant combination in post-FMT patients. [248]
• Selective beta-1 antagonists (metoprolol, bisoprolol) produce less pronounced gut motility effects than non-selective agents and may be preferable in patients with pre-existing motility vulnerability. [245]

Patient Guidance

• Continue beta-blockers as prescribed throughout FMT treatment — do not modify cardiovascular medications without explicit physician instruction.
• Report bloating, abdominal distension, or significant changes in bowel frequency during beta-blocker therapy to your clinical team.
• Maintain dietary fibre intake ≥25g/day to support colonic transit and fermentation dynamics despite motility-slowing effects.
• If you are taking both a beta-blocker and a proton pump inhibitor, discuss the necessity of ongoing PPI use with your clinical team — this combination carries compounded risk for bacterial overgrowth.
• Physical activity within your cardiovascular tolerance counteracts beta-blocker-mediated motility slowing and actively supports gut microbial diversity.
• If your beta-blocker type changes during FMT consolidation, notify the clinical team — different agents have meaningfully different effects on gut wall physiology.

References

[245] Vandeputte D, Falony G, Vieira-Silva S et al. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016. Link

This study correlated Bristol Stool Scale-based stool consistency with gut microbiota profiles in 53 healthy women by 16S rDNA Illumina sequencing. Stool consistency strongly correlated with major microbiome markers: it was negatively correlated with species richness, positively with the Bacteroidetes:Firmicutes ratio, and linked to Akkermansia and Methanobrevibacter abundance. Microbiota growth-potential analysis supported transit time as a selective force on bacterial growth rates. The findings establish stool consistency as a critical confounder in microbiome disease-marker studies.

[246] Freestone PPE, Sandrini SM, Haigh RD, Lyte M. Microbial endocrinology: how stress influences susceptibility to infection. Trends Microbiol. 2008. Link

This review introduces microbial endocrinology, the intersection of microbiology with mammalian endocrinology and neurophysiology, demonstrating that microorganisms have evolved to use widely distributed neurohormones as environmental cues for growth and pathogenesis. The review documents that responsiveness to human stress hormones is widespread across the microbial world, providing a mechanistic framework for stress-driven changes in infectious disease susceptibility. The findings establish microbial endocrinology as a tractable lens for understanding stress-infection interactions.

[247] Sandek A, Bauditz J, Swidsinski A et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 2007. Link

This case-control study assessed gut morphology and function in 22 chronic heart failure (CHF) patients (LVEF 31+/-1%, NYHA 2.3+/-0.1, peak VO2 15.0+/-1.0 ml/kg/min) versus 22 controls. CHF patients showed significantly thickened bowel walls (terminal ileum 1.48+/-0.16 vs 1.04+/-0.08 mm; descending colon 2.59+/-0.18 vs 1.43+/-0.13 mm; sigmoid 2.97+/-0.27 vs 1.64+/-0.14 mm; all p<0.01), with increased small and large bowel permeability and altered mucosal bacterial biofilm. The findings support gut barrier dysfunction and bacterial translocation as drivers of CHF-associated inflammation.

[248] Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020. Link

This clinical guideline assesses the diagnosis and treatment of small intestinal bacterial overgrowth (SIBO), defined as excessive small-bowel bacteria causing GI symptoms. The evidence-based recommendations were developed using the GRADE process, with expert consensus where formal grading was not feasible. The guideline defines optimal diagnostic methods, including breath testing and small-bowel aspirate culture, and reviews antibiotic and adjunctive treatment options. The document provides a practical framework for clinical decision-making in suspected SIBO.